Maridebart Cafraglutide
Sources
publication, as of 2025-06-23Stale
https://pubmed.ncbi.nlm.nih.gov/40549887/
Maridebart cafraglutide is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism. It was given subcutaneously. In the obesity cohort, the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% to -16.2% with maridebart cafraglutide, as compared with -2.5% with placebo.
N Engl J Med 2025;393:843-857, PMID 40549887, abstract
registry, as of 2026-01-20Stale
https://clinicaltrials.gov/study/NCT05669599
Protocol section, NCT05669599, last update posted 2026-01-20
registry, as of 2026-09-17Stale
https://clinicaltrials.gov/study/NCT06858839
Protocol section, NCT06858839 MARITIME-1, last update posted 2026-09-17
registry, as of 2026-10-29Stale
https://clinicaltrials.gov/study/NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 12800. Conditions Atherosclerotic Cardiovascular Disease; Overweight; Obesity. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
ClinicalTrials.gov NCT07037433 protocol and results modules
registry, as of 2026-10-29Stale
https://clinicaltrials.gov/study/NCT07037459
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 5056. Conditions Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with pres
ClinicalTrials.gov NCT07037459 protocol and results modules
registry, as of 2026-10-05Stale
https://clinicaltrials.gov/study/NCT07684235
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 3200. Conditions Obesity; Overweight. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
ClinicalTrials.gov NCT07684235 protocol and results modules
registry, as of 2025-12-31Stale
https://clinicaltrials.gov/study/NCT06858878
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 1105. Conditions Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight. The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
ClinicalTrials.gov NCT06858878 protocol and results modules
registry, as of 2026-10-05Stale
https://clinicaltrials.gov/study/NCT07684144
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 950. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
ClinicalTrials.gov NCT07684144 protocol and results modules
registry, as of 2026-11-06
https://clinicaltrials.gov/study/NCT07575399
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 300. Conditions Obesity or Overweight. Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
ClinicalTrials.gov NCT07575399 protocol and results modules
registry, as of 2025-12-17Stale
https://clinicaltrials.gov/study/NCT06987695
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 279. Conditions Obesity Disease. The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
ClinicalTrials.gov NCT06987695 protocol and results modules
registry, as of 2026-10-06Stale
https://clinicaltrials.gov/study/NCT07225686
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 250. Conditions Obesity; Obstructive Sleep Apnea. This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or
ClinicalTrials.gov NCT07225686 protocol and results modules
registry, as of 2026-09-29Stale
https://clinicaltrials.gov/study/NCT07226765
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 250. Conditions Obstructive Sleep Apnea. This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
ClinicalTrials.gov NCT07226765 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07871409
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 230. Conditions Obesity; Overweight. The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
ClinicalTrials.gov NCT07871409 protocol and results modules
registry, as of 2026-09-11Stale
https://clinicaltrials.gov/study/NCT06660173
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Amgen. Enrollment 409. Conditions Type 2 Diabetes Mellitus (T2DM). The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
ClinicalTrials.gov NCT06660173 protocol and results modules
registry, as of 2026-09-28Stale
https://clinicaltrials.gov/study/NCT07441252
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Amgen. Enrollment 180. Conditions Overweight or Obesity and Elevated Liver Fat. The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with r
ClinicalTrials.gov NCT07441252 protocol and results modules
registry, as of 2026-11-06
https://clinicaltrials.gov/study/NCT07921316
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Amgen. Enrollment 356. Conditions Obesity; Overweight. The main objective of this study is to compare the pharmacokinetics of maridebart cafraglutide administered as a single dose using two different subcutaneous (SC) presentations in participants with overweight or obesity after they have received escalating doses of the study drug.
ClinicalTrials.gov NCT07921316 protocol and results modules
registry, as of 2026-08-07Stale
https://clinicaltrials.gov/study/NCT07313761
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Amgen. Enrollment 349. Conditions Overweight and Obesity. The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
ClinicalTrials.gov NCT07313761 protocol and results modules
registry, as of 2026-06-17Stale
https://clinicaltrials.gov/study/NCT07226778
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Amgen. Enrollment 348. Conditions Overweight; Obesity. The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
ClinicalTrials.gov NCT07226778 protocol and results modules